Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Lomitapide in Healthy Subjects.

NCT ID: NCT02080455

Last Updated: 2020-03-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 32 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-01-27
• Study Completion Date: 2014-03-07

Brief Summary

The primary objective of this study is to assess the effect of atorvastatin, a weak cytochrome P450 (CYP) 3A4 inhibitor, on the pharmacokinetics (PK) of lomitapide and its 2 primary metabolites, M1 and M3.

Detailed Description

This study will be a single center, randomized, open-label, 2-arm study to evaluate the effects of atorvastatin, a weak CYP3A4 inhibitor, on the PK of lomitapide in healthy male and female subjects when atorvastatin is administered simultaneously with lomitapide and when it is administered 12 hours after lomitapide.

Conditions

Effect of Atorvastatin on the Pharmacokinetics of Lomitapide

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Lomitapide & Atorvastatin - Taken Together

2 single oral doses of lomitapide (20 mg) with a 14-day washout between (Day 1 & Day 15)

11 single oral doses of atorvastatin (80 mg) (Day 11 through day 21)

Group Type: EXPERIMENTAL

lomitapide

Intervention Type: DRUG

20 mg dose

Atorvastatin

Intervention Type: DRUG

80 mg

Lomitapide & Atorvastatin - Approx. 12 hours between

2 single oral doses of lomitapide (20 mg) with a 14-day washout between (Day 1 & Day 15)

11 single oral doses of atorvastatin (80 mg) (Day 12 through day 22)

Group Type: EXPERIMENTAL

lomitapide

Intervention Type: DRUG

20 mg dose

Atorvastatin

Intervention Type: DRUG

80 mg

Interventions

lomitapide

20 mg dose

Intervention Type: DRUG

Atorvastatin

80 mg

Intervention Type: DRUG

Other Intervention Names

Juxtapid; Lipitor

Eligibility Criteria

Inclusion Criteria

1. Healthy males and females, between 18 and 55 years of age inclusive

2. BMI between 18.5 and 32.0 kg/m2, inclusive; total body weight of >110 lbs (50 kg);

3. in good health, determined by no clinically significant or relevant abnormalities identified by a detailed medical history and medical exam

4. creatine phosphokinase, AST, and ALT levels must be below 1.5 times the upper limit of normal

5. clinical laboratory evaluations within the reference range for the test laboratory

6. negative test for selected drugs of abuse

7. negative hepatitis panel and negative HIV antibody screens

8. males will either be sterile or agree to use approved methods of contraception

9. all females must have a negative serum beta human chorionic gonadotropin pregnancy test and will be required to use a medically acceptable method of contraception.

10. able to comprehend and willing to sign an Informed Consent Form

Exclusion Criteria

1. significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, GI, neurological, or psychiatric disorder

2. history of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance

3. history of stomach or intestinal surgery or resection

4. history of Gilbert's Syndrome or suspicion of Gilbert's Syndrome

5. subjects who have an abnormality in the 12-lead ECG

6. use of any drugs of abuse for 6 months prior to Check-in;

7. subjects who consume more than 14 units of alcohol per week or who have a significant history of alcoholism or drug/chemical abuse within 1 year prior to Check-in

8. use of any tobacco- or nicotine-containing products within 6 months prior to Check-in;

9. participation in any other investigational study drug trial within 30 days prior to Check-in;

10. use of any prescription medications/products within 14 days prior to Check-in unless deemed acceptable by the Investigator and Sponsor

11. use of any over-the-counter, nonprescription preparations within 7 days prior to Check-in, unless deemed acceptable by the Investigator and Sponsor

12. use of alcohol-, grapefruit- (including star fruit), or caffeine-containing foods or beverages within 72 hours prior to Check-in and through Study Completion

13. poor peripheral venous access;

14. donation of blood (500 mL) from 30 days prior to Screening through Study Completion

15. receipt of blood products within 2 months prior to Check-in;

16. any acute or chronic condition, scheduled hospitalization (inclusive of elective surgery during study) or scheduled travel prior to completion of all study procedures which, in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in this clinical study;

17. subjects who, in the opinion of the Investigator, should not participate in this study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Aegerion Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Mark Sumeray, MD

Role: STUDY_CHAIR

Cheif Medical Officer

T. Alex King, MD, CPI

Role: PRINCIPAL_INVESTIGATOR

Covance

Locations

Covance Clinical Research Unit, Inc

Dallas, Texas, United States

Countries

United States

Other Identifiers

AEGR-733-024

Identifier Type: -

Identifier Source: org_study_id